Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Status:
Completed
Trial end date:
2019-04-24
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of recombinant human serum albumin /
granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced
neutropenia